icd 10 code for waldenstrom's macroglobulinemia

What is the CPT code for Waldenstrom macroglobulinemia?

Oct 01, 2021 · C88.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Waldenstrom macroglobulinemia; The 2022 edition of ICD-10-CM C88.0 became effective on October 1, 2021. This is the American ICD-10-CM version of C88.0 - other international versions of ICD-10 C88.0 may differ.

What is the ICD 10 code for macroglobulinemia?

ICD-10-CM Code for Waldenstrom macroglobulinemia C88.0 ICD-10 code C88.0 for Waldenstrom macroglobulinemia is a medical classification as listed by WHO under the range - Malignant neoplasms . Subscribe to Codify and get the code details in a flash.

What is the ICD 10 code for chondromalacia?

ICD-10-CM Code C88.0 Waldenstrom macroglobulinemia BILLABLE | ICD-10 from 2011 - 2016 C88.0 is a billable ICD code used to specify a diagnosis of waldenstrom macroglobulinemia. A 'billable code' is detailed enough to be used to specify a medical diagnosis. The ICD code C880 is used to code Waldenström's macroglobulinemia

What is lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia?

273.3 Macroglobulinemia Corresponding ICD-10 Codes C88.0 Waldenstrom macroglobulinemia Corresponding ICD-10-CM Codes (U.S. only) C88.0 Waldenstrom macroglobulinemia (effective October 01, 2015) Signs and Symptoms Adenopathy Confusion Dizziness Easy bruising or bleeding (nosebleeds or bleeding from gums) Elevated lymphocyte s in blood

What is Waldenstrom's Macroglobulinemia?

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL). The cancer cells make large amounts of an abnormal protein (called a macroglobulin). Another name for WM is lymphoplasmacytic lymphoma.Jul 19, 2018

Is Waldenstrom Macroglobulinemia a blood cancer?

Overview. Waldenstrom macroglobulinemia (mak-roe-glob-u-lih-NEE-me-uh) is a rare type of cancer that begins in the white blood cells. If you have Waldenstrom macroglobulinemia, your bone marrow produces too many abnormal white blood cells that crowd out healthy blood cells.Aug 18, 2020

Is Waldenstrom a form of leukemia?

If your doctor says you have Waldenstrom's macroglobulinemia, it means you have a rare blood cancer that usually spreads slowly. It's also called lymphoplasmacytic lymphoma (LPL). This disease is a kind of non-Hodgkin's lymphoma.Mar 22, 2021

What are the symptoms of Waldenstrom macroglobulinemia?

Symptoms can include heart palpitations, feeling tired and weak, cough, shortness of breath, rapid weight gain, and swelling in the feet and legs. Infections: The high levels of abnormal antibody in WM can slow the body's normal antibody production. This makes it harder for the body to fight infections.Jul 19, 2018

Is Waldenstrom inherited?

Waldenström macroglobulinemia is not inherited, and most affected people have no history of the disorder in their family. The condition usually arises from genetic changes in blood cells that are acquired during a person's lifetime (somatic variants), which are not inherited.Sep 24, 2021

What are the end stages of Waldenstrom's?

Staging/Prognostic Scoring System for Waldenstrom Macroglobulinemia/Lymphoplasmacytic LymphomaScoreStage3-year WM-related mortality1Low10%2Intermediate14%3High38%4-5Very high48%1 more row•Dec 21, 2020

How is Waldenstrom macroglobulinemia diagnosis?

Blood tests can help your doctor diagnose Waldenstrom macroglobulinemia. An increase in IgM can be found by protein electrophoresis, which is a method of separating proteins in the blood with an electric field. Biopsy. A biopsy is the removal of a small amount of tissue for examination under a microscope.

Is Waldenstrom macroglobulinemia a type of CLL?

Abstract. Among small lymphocyte cell disorders, B-chronic lymphocytic leukemia (B-CLL), small lymphocytic lymphoma (SLL), and lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/MW) are included. B-CLL patients always have blood and bone marrow (BM) involvement by a CD5+ B lymphocyte.

Is Waldenstrom's an autoimmune disease?

Waldenström macroglobulinemia represents a lymphoplasmacytic lymphoma with an indolent clinical course. The existing literature associates this hematologic malignancy with various autoimmune disorders. Notwithstanding, these autoimmune conditions have not been comprehensively characterized or systematized to date.

What is the life expectancy of someone with Waldenstrom's macroglobulinemia?

Median survivalISSWM risk groupMedian survival*Low12 yearsIntermediate8 yearsHigh3.5 yearsOct 17, 2018

Is Waldenstrom a rare disease?

Waldenstrom macroglobulinemia (WM) is rare, with an incidence rate of about 3 cases per million people per year in the United States. About 1,000 to 1,500 people are diagnosed with WM each year in the United States.Jul 19, 2018

How do you get Waldenstrom?

The DNA changes found in WM cells are usually acquired after birth (not passed on from a parent). Some of these acquired changes may have outside causes, but often they occur for no apparent reason. They seem to happen more often as we age, which might help explain why WM usually occurs in older people.Jul 19, 2018

What is the approximate match between ICd9 and ICd10?

This means that while there is no exact mapping between this ICD10 code C88.0 and a single ICD9 code, 273.3 is an approximate match for comparison and conversion purposes.

What is Waldenström's macroglobulinemia?

Waldenström's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) is cancer affecting B cells, a type of white blood cell. The main attributing antibody is immunoglobulin M (IgM). WM is an "indolent lymphoma," (i.e., one that tends to grow and spread slowly).

What is inclusion term?

Inclusion Terms are a list of concepts for which a specific code is used. The list of Inclusion Terms is useful for determining the correct code in some cases, but the list is not necessarily exhaustive.

What is Waldenstrom Macroglobulinemia?

Waldenstrom Macroglobulinemia (WM) is a subset of lymph oplasmacytic lymphoma. Patients with WM have IgM ( immunoglobulin M) in their blood and/or bone marrow. IgM is also called IgM monoclonal gammopathy. There will also be an increased number of lymphocyte s in the blood.

Is Waldenstrom macroglobulinemia a monoclonal gammopathy?

Waldenstrom macroglobulinemia (WM) is found in a substantial subset of patients with LPL, but is not synonymous with it; it is defined as LPL with bone marrow involvement and an IgM monoclonal gammopathy of any concentration.

What is Waldenström macroglobulinemia?

Waldenström macroglobulinemia Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma.

What is the condition that causes a loss of sensation and weakness in the limbs?

Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy).

What is the name of the disease that causes abnormal cells to produce large amounts of IgM?

These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia").Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer.

Why do I get tired when I'm in Waldenström?

Excessive tiredness (fatigue) due to a reduction in red blood cells (anemia) is common in affected individuals.People with Waldenström macroglobulinemia have an increased risk of developing other cancers of the blood or other tissues.

What is lymphoma cancer?

Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.

Why do my hands and feet turn white?

These proteins are then referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures.

How to diagnose lymphoma?

Pain, swelling or a feeling of fullness in the abdomen. Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood.

What is WM/LPL?

Cornell and colleagues (2017) noted that Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. These researchers evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013). Patients received MAC (n = 67) or RIC (n = 67). Median age at alloHCT was 53 years, and median time from diagnosis to transplantation was 41 months; 13 % (n = 18) failed prior autologous HCT. 57 % (n = 82) had chemo-sensitive disease at the time of transplantation, whereas 22 % had progressive disease. Rates of PFS, OS, relapse, and non-relapse mortality at 5 years were 46 %, 52 %, 24 %, and 30 %, respectively. Patients with chemo-sensitive disease and better pre-transplant disease status experienced significantly superior OS. There were no significant differences in PFS based on conditioning (MAC = 50 %, versus RIC = 41 %) or graft source. Conditioning intensity did not impact treatment-related mortality or relapse. The most common causes of death were primary disease and GVHD. The authors concluded that alloHCT yielded durable survival in select patients with WM/LPL. They stated that strategies to reduce mortality from GVHD and post-transplant relapse are needed to improve this approach.

What is Waldenstrom macroglobulinemia?

Waldenstrom macroglobulinemia (WM) is a distinct indolent B-cell lympho-proliferative malignancy characterized by IgM para-proteinemia. It accounts for 1 to 2 % of hematologic malignancies, with an estimated 1,500 new cases annually in the United States. The median age of WM patients at presentation is 63 to 68 years; with men comprising 55 to 70 % of cases. Although the disease is sensitive to chemo-immunotherapy, it remains incurable and affected patients have a median survival of 5 to 10 years. Risk-stratification in newly diagnosed patients should start with a prognostic evaluation based on the International Prognostic Scoring System for WM to identify those patients in whom particularly poor survival with chemotherapy is expected and in whom alternative treatment strategies, such as hematopoietic cell transplantation (HCT), should be considered. The hyper-viscosity syndrome associated with WM is a clinical emergency due to elevated levels of IgM resulting in decreased flow and impaired microcirculation of the central nervous system. Although the diagnosis is established by measuring serum viscosity, clinicians should render the decision to initiate treatment with plasmapheresis on the basis of the patient's symptoms and physical findings (e.g., blurred vision, dizziness, headaches, paresthesias, oro-nasal bleeding, papilledema, retinal vein engorgement and flame-shaped hemorrhages, as well as stupor and coma), rather than on the magnitude of the viscosity measurement (Bachanova and Burns, 2012; Rajkumar, 2012).

What drugs are used for WM?

Given WM's natural history, reduction of therapy toxicity is an important part of treatment selection. Bortezomib, fludarabine, thalidomide, everolimus, ibrutinib, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in relapsed WM.

Is Rituximab monotherapy the same as bendamustine?

Rituximab-monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or ibrutinib. Purine nucleoside analogs are active but usage is declining for less toxic alternatives. The preferred Mayo Clinic induction is rituximab and bendamustine.